COVID-19 Vaccine Q&A Panel

COVID-19 Vaccine Q&A Panel

Your chance to ask the experts

As Australians are now receiving the COVID-19 Vaccine, you may have some questions about the roll out of the vaccine and people diagnosed with allergic disease. Join us on Monday 15th March in a live Q&A Panel discussion with Prof Michael Gold and Prof Michaela Lucas about the COVID-19 vaccine.

Tune in to understand more about the vaccine and have your questions answered by the experts. There will be opportunity to ask questions during the session, however you are encouraged to submit your questions via the registration form below.

The Q&A session will be recorded and put on our website after the event.

Webinar Details

Date: Monday, 15 March 2021

Time: 8.00-9.00pm AEDT

About the panellists

Prof Mike GoldProfessor Michael Gold MbChB, DCH, FCP, MD, FRACP

Professor Michael Gold is a Paediatric Allergist and Immunologist with conjoint positions in the Discipline of Paediatrics, University of Adelaide and is former Medical Unit Head of the Department of Allergy and Immunology at the Women’s and Children’s Health Network.  He has a research and clinical interest in the prevention of food allergy and vaccine safety.  He was appointed to the World Health Organisation Global Advisory Committee for Vaccine Safety in 2010 and has been an advisor to the Australian Therapeutic Goods Administration via his appointment to a number of expert advisory groups since 2006.  He has been awarded a number of Australian national research grants as a principal investigator for projects that have researched novel methods of safety surveillance including data linkage and m-Health.  He has contributed to a number of key WHO guidelines which include the global Adverse Event Following Immunisation surveillance manual, the WHO guideline on causality assessment, a guideline for programme managers on Immunisation stress related responses and the global manual for COVID vaccine safety surveillance.  He has participated in numerous WHO organised training courses to strengthen adverse event surveillance and causality assessment systems in low and middle income countries and is currently a consultant to WHO South East Asian Region, facilitating the implementation of COVID vaccine pharmacovigilance.  He has contributed to the Vaccines for Africa initiative through research collaborations and presentations at the annual vaccinology course based at the University of Cape Town.       

Michaela Lucas Dr Med MD, FRACP, FRCPA

Prof Michaela LucasProfessor Michaela Lucas is an Immunologist/Immunopathologist and Clinician-Scientist with expertise spanning T cell immunology including the pathogenesis of T cell mediated drug allergies, anti-viral T cell responses, vaccine development, and most recently understanding the role of inflammation in the development of adaptive immunity in organ transplantation. She leads a multi-disciplinary team of clinical and basic science researchers, microsurgeons and technicians, at the Immunology and Transplantation Lab at The University of Western Australia.

Professor Lucas’s research has produced over 100 peer-reviewed papers. She has held multiple NHMRC and ACH2 grants as a principle and co-investigator, and is currently Principal Investigator at the Sir Charles Gairdner Hospital site for the multi-centre BRACE Clinical trial, investigating the BCG vaccination to reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure. In addition, Professor Lucas is conducting two investigator-driven randomised controlled trials in antibiotic allergy. She is the President of the Australasian Society of Immunology and Allergy (ASCIA), the Chair of the ASCIA Drug Allergy Committee, and the project lead in Drug Allergy for the National Allergy Strategy. She consults for the Australian Digital Health Agency on the My Health Record initiative and the Australian Health and Safety Agency on drug allergy documentation.

Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond


Viatris
Sanofi
Nestle
Allergy Concepts

Platinum


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer

Gold


  • dbv technologies
  • Mondelez
  • Nurticia
Silver

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William


© 2023 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 



ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.


ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.